As the S&P/ASX 200 index is set to open lower, mirroring Wall Street's overnight declines amid rising oil prices and geopolitical tensions, investors are closely monitoring market movements and economic indicators. In this environment of cautious optimism, growth companies with high insider ownership can offer a compelling investment narrative, as they often align management interests with shareholder value while potentially delivering substantial earnings growth.
| Name | Insider Ownership | Earnings Growth |
| Wisr (ASX:WZR) | 10.2% | 88.3% |
| Titomic (ASX:TTT) | 14.7% | 71.3% |
| Starpharma Holdings (ASX:SPL) | 21.8% | 91.8% |
| SKS Technologies Group (ASX:SKS) | 28.2% | 42.9% |
| Predictive Discovery (ASX:PDI) | 10.4% | 63.6% |
| Forrestania Resources (ASX:FRS) | 32.3% | 126.7% |
| Austral Resources Australia (ASX:AR1) | 22.9% | 33.1% |
| Auric Mining (ASX:AWJ) | 19.7% | 29.2% |
| Adveritas (ASX:AV1) | 17.6% | 107.8% |
| Advanced Engineered Materials (ASX:AEM) | 35.1% | 48.5% |
Let's uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Chrysos Corporation Limited develops and supplies mining technologies across Europe, the Middle East, Africa, the Asia Pacific, and the Americas with a market cap of A$906.46 million.
Operations: Chrysos Corporation Limited generates its revenue through the development and provision of advanced mining technologies across various global regions, including Europe, the Middle East, Africa, the Asia Pacific, and the Americas.
Insider Ownership: 13.6%
Earnings Growth Forecast: 34.9% p.a.
Chrysos Corporation Limited has shown a strong turnaround with sales rising to A$88.11 million and achieving profitability with a net income of A$1.79 million for the fiscal year ending June 2026. Despite no substantial insider buying recently, the company remains attractive due to its forecasted earnings growth of 34.9% annually, outpacing both its revenue growth and the Australian market average. However, insider selling has been significant recently, which may warrant caution.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Clarity Pharmaceuticals Ltd (ASX:CU6) is a clinical stage radiopharmaceutical company focused on developing radiopharmaceutical products for oncology in Australia and the United States, with a market capitalization of A$1.05 billion.
Operations: The company generates revenue from its radiopharmaceutical development segment, amounting to A$10.58 million.
Insider Ownership: 13%
Earnings Growth Forecast: 21.5% p.a.
Clarity Pharmaceuticals is poised for significant growth, with its revenue expected to rise by 50.1% annually, outpacing the Australian market. The company anticipates becoming profitable within three years, surpassing average market growth rates. Recent developments include promising results from the SECuRE trial for prostate cancer treatment and a substantial A$9.76 million R&D Tax Incentive refund, enhancing its financial position to advance its Targeted Copper Theranostic platform despite no recent insider trading activity reported.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: GemLife Communities Group (ASX:GLF) is an Australian company that develops, builds, owns, and operates land lease communities, with a market cap of A$1.67 billion.
Operations: The company's revenue is primarily derived from its Development segment, which contributes A$259.83 million, and its Community Operations segment, which adds A$21.86 million.
Insider Ownership: 26.7%
Earnings Growth Forecast: 21.4% p.a.
GemLife Communities Group is on a growth trajectory with earnings forecasted to rise by 21.4% annually, outpacing the Australian market's average. Recent governance enhancements include appointing Louise Bolger as Company Secretary, strengthening risk management. Despite revenue growth of 5.8% last year and projected annual revenue growth of 14.4%, debt coverage remains a concern, and the stock trades at a significant discount to its estimated fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com